

### **Amendments to the Specification:**

Please amend the specification as follows:

Page 42, lines 19-22:

A polyhistidine sequence was prepared synthetically with *Nde*I, *Nsi*I and *Bsp*MI sites, and ligated into pARCPAH to produce plasmid pARCP2-6H which encodes cyclo-[CHMHHHHHGAGAA] (SEQ ID No.: 3).

Page 44, lines 13-17:

Synthesis of cyclo-[Ser-Gly-Gly-Tyr-Leu-Pro-Pro-Leu] (SEQ ID No.: 4)

To a solution of 3.5 mg (4  $\mu$ mol) of  $\text{NH}_2$ -Ser-Gly-Gly-Tyr-Leu-Pro-Pro-Leu- $\text{CO}_2\text{H}$  (SEQ ID No.: 4) and 1.8 mg (16  $\mu$ mol) of N-hydroxysuccinimide in 20 ml of dimethylformamide was added 3.0 mg (16  $\mu$ mol) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).

Page 46 line 23, through to page 47, lines 1-2:

To produce pseudostellarin F (cyclo-[SGGYLPPL]) (SEQ ID No.: 4), the vector was modified by silent mutation to create an *Afl*III site at the 5'-end of the  $I_N$  gene (d in Fig. 3).